ASX:IMMPharmaceuticals, Biotechnology & Life SciencesBiotechnology
Immutep Ltd
$0.057
+$0.006 (+11.76%)
Day Range
$0.056 – $0.066
52 Week Range
$0.028 – $0.470
Volume
51.51M
Avg Volume (10D)
8.73M
Market Cap
$84.00M
Price Chart
Market Statistics
Open$0.058
Previous Close$0.051
Day High$0.066
Day Low$0.056
52 Week High$0.470
52 Week Low$0.028
Valuation
Market Cap84.00M
Shares Outstanding1.47B
Price to Book0.76
Trading Activity
Volume51.51M
Value Traded3.09M
Bid$0.056 × 1,427,657
Ask$0.057 × 428,199
Performance
1 Day-1.92%
5 Day-7.27%
13 Week27.50%
52 Week-78.75%
YTD-87.71%
Technical Indicators
RSI (14)57.04
50-Day SMA$0.054
200-Day SMA$0.221
Latest News
Biotechnology
Immutep Granted FDA Orphan Drug Designation for Efti in Soft Tissue Sarcoma
Immutep wins FDA Orphan Drug Designation for eftilagimod alfa in soft tissue sarcoma, boosting exclusivity and regulatory support as TACTI-004 winds down.
Hot Topics
Weekly Wrap: Shares fall another 2.6% for the week as conflict worsens
ASX 200 slides 2.6% this week to 8,617 as Iran-Israel conflict lifts oil above $100; NST and SYR plunge, while EOS soars on a Middle East contract.
Biotechnology
Immutep Discontinues TACTI-004 Phase III Trial Due to Futility
Immutep halts TACTI-004 Phase III in first-line NSCLC due to futility; shares resume trading as cash runway extends beyond Q2 CY2027.
Biotechnology
Immutep TACTI-004 NSCLC Trial At 50% Enrolment, Paving Way for Futility Analysis
Immutep (ASX: IMM) has achieved a significant milestone, announcing 50% patient enrolment in its global Phase III TACTI-004 trial for first-line non-small ce